구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous immune Cells (Autologous immune Cells) Liaoning Medical Diagnosis and Tre…·Lung Cancer (Locally Advanced or M… 31 trials |
|---|---|
Overview Program | Autologous immune Cells |
Overview Company | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
Overview Modality | CGT |
Overview Target | Lung Cancer (Locally Advanced or Metasta |
Overview Indication | Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e |
MoA Mechanism | checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death |
MoA Biomarker | biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.. BACKGROUND: Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking… |
Toxicology CRS | grade 4 |
Clinical Safety signal | Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.. BACKGROUND: Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking… |
Clinical Reported OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT00787761 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00787761 |
Preclinical Animal (cat.) | Human, Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous immune Cells (Autologous immune Cells) Liaoning Medical Diagnosis and Tre…·Lung Cancer (Locally Advanced or M… 31 trials |
|---|---|
Overview Program | Autologous immune Cells |
Overview Company | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
Overview Modality | CGT |
Overview Target | Lung Cancer (Locally Advanced or Metasta |
Overview Indication | Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e |
MoA Mechanism | checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death |
MoA Biomarker | biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.. BACKGROUND: Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking… |
Toxicology CRS | grade 4 |
Clinical Safety signal | Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.. BACKGROUND: Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking… |
Clinical Reported OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT00787761 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00787761 |
Preclinical Animal (cat.) | Human, Mouse, In vitro |
추천 비교
추천 비교